Phase I Study of Cladribine, Cytarabine (Ara-C), Granulocyte Colony Stimulating Factor (G-CSF) (CLAG Regimen) and Simultaneous Escalating Doses of Imatinib Mesylate (Gleevec) in Relapsed/Refractory AML

Background: Receptor activated tyrosine kinases like c-kit, c-fms and PDGFR are known targets of inhibition by imatinib mesylate (Gleevec) and are expressed on AML blasts. Marrow stromal cells and monocytes express the ligands KIT ligand, M-CSF and PDGF capable of activating survival pathways in the...

Full description

Bibliographic Details

Published in:	Blood Vol. 108; no. 11; p. 1958
Main Authors:	Abboud, Camille N., Walker, Alison, Komrokji, Rami S., Ifthikharuddin, Jainulabdeen J., Sparks, Connie, Likly, Kelly, Messina, Patti, Mulford, Deborah, Friedberg, Jonathan, Becker, Michael W., Young, Faith, Bernstein, Steven H., Salvado, August J., Phillips, Gordon L., Liesveld, Jane L.
Format:	Journal Article
Language:	English
Published:	Elsevier Inc 16-11-2006
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!